Big Data and AI Can Guide Cannabis Medicine
Robin Lefferts
August 30th, 2021
App, Exclusive, News, Top Story
In order for cannabis medicine to make the big leap to mainstream acceptance, a few things likely have to take place. Doctors, not just cannabis providers, need to become more comfortable discussing and prescribing the plant. Regulations need to become more homogenous and universal, like the pharmaceutical industry. Pharma companies need to advance more cannabis-derived medicines for approval.
In order for those things to happen, robust data around the efficacy of cannabis treatments needs to be gathered and widely understood. In the meantime, cannabis patients and providers are often stuck with a personal trial-and-error approach to finding the right treatment for their own needs. RYAH Group Inc. (CSE: RYAH) is one company that is pushing forward in all of these areas. The company’s smart delivery devices, database with over 200,000 users, and artificial intelligence-powered data engine combine to form a powerful Internet of Things solution with the potential to more fully legitimize cannabis medicine while making it more effective for current patients.
Moving the Industry Forward
Regulators like the United States Food and Drug Administration (FDA) need data to make informed decisions. Big pharma companies need data to even undertake research programs aimed at developing new potential drugs. Doctors need data to feel comfortable giving prescriptions or recommendations for treatment.
Since the cannabis industry is so young, was prohibited for so long, and still faces a myriad of patchwork and inconsistent regulations, cannabis medicine is severely lacking the large datasets that are crucial for the industry’s development. In this regard, RYAH is well-positioned to provide all interested parties with the information necessary for growth and advancement.
RYAH’s Data Sharing Benefits
The company’s smart devices and data solutions are gaining traction with cannabis researchers across the globe. The controlled dosing, easily recorded personal feedback from patients, wealth of data stored in RYAH’s Cloud database, and AI-powered data interpretation and organization give researchers tools that make their studies more effective and efficient. RYAH is involved in trials and studies in Britain, Italy, Italy again, and the Channel Islands. The company also has deals in France and New Zealand for distribution and potential inclusion in clinical trials and major studies.
RYAH’s goal is to provide regulators, researchers, and drug companies all the data they need to mainstream plant-based medicine, and it looks like the company is on its way.
Click here to receive an investor presentation and corporate updates
Improving the Patient Experience
RYAH’s smart devices, connected apps, and AI data interpreter can help patients and doctors effectively hone a treatment regimen according to the patient’s own feedback combined with that of the other users in the system. Without the insights from a large patient pool and the ability to easily record, track, and interpret personal experiences and preferences, many cannabis patients can get a little lost. Which strain? What is the proper dose? Has this particular type of treatment worked for other people?
Watch how Ryah technology Benefits to Patients and Doctors
RYAH’s system offers control and assurance, not only to researchers and patients involved in clinical trial programs but also to normal, everyday medical cannabis users in search of a little guidance. To many, using cannabis presents a great unknown fraught with risks. RYAH helps to alleviate those concerns and bring the cannabis patient experience more in line with that of conventional patients.
The Takeaway
This type of system is right in line with the larger trend toward tele-health and the use of machine learning and artificial intelligence to improve patient outcomes. Overall, the market for remote treatment is growing at a 26.5% CAGR, expected to reach $475 billion in the next five years. It’s a huge trend in healthcare, and RYAH is at the forefront of the movement in the cannabis industry.
The two aspects of RYAH’s business go hand in hand, improving treatments for cannabis patients while providing data and a platform that enables research and regulation that will further legitimize the industry as a whole. Keep an eye out for continued developments in the RYAH story.
Click here to receive an investor presentation and corporate updates
Disclaimer
The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: https://cannabisfn.com/legal-disclaimer/
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
About Robin Lefferts
Robin Lefferts has been involved in the legal cannabis industry since 2012, sometimes as an active participant and always as an interested observer.
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
Matt Hawkins is the founder and managing principal of Cresco Capital Partners, LLC (“Cresco”), a private equity firm focused specifically on investing in the legalized cannabis industry. Since its inception in the summer of 2015, Cresco has made 14 investments out of its first fund and is currently raising this fund, Fund II. Prior to the […]
Technical420 is the premier provider of research and analysis on cannabis stocks. We provide investors with sponsored and non-sponsored information on the volatile and emerging cannabis industry. “Our research is our passion!” Your profit is our reward!
Mojave Jane Brands Inc. is a Canadian-based cannabis sector brand and distribution company emerging as a true vertical integrator in California’s legal cannabis space serving recreational and wellness markets. The Company’s U.S. holdings are comprised of assets set up as a vertical stack including cultivation to scale, branding, packaging, manufacturing & processing, as well as, […]
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
